Our top pick for
NCS Multistage Holdings Inc is an oil & gas equipment & services business based in the US. NCS Multistage shares (NCSM) are listed on the NASDAQ and all prices are listed in US Dollars. NCS Multistage employs 191 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.97|
|52-week range||$11.83 - $39.20|
|50-day moving average||$27.17|
|200-day moving average||$27.28|
|Wall St. target price||$34.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.74|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-0.37%|
|1 month (2021-09-24)||10.96%|
|3 months (2021-07-23)||-3.91%|
|6 months (2021-04-23)||24.93%|
|1 year (2020-10-23)||3,691.75%|
|2 years (2019-10-23)||1,398.50%|
|3 years (2018-10-23)||168.07%|
|5 years (2016-10-20)||N/A|
Valuing NCS Multistage stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NCS Multistage's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NCS Multistage's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.2 million.
The EBITDA is a measure of a NCS Multistage's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$93.7 million|
|Gross profit TTM||$44.1 million|
|Return on assets TTM||-6.26%|
|Return on equity TTM||9.27%|
|Market capitalisation||$71.6 million|
TTM: trailing 12 months
There are currently 4,179 NCS Multistage shares held short by investors – that's known as NCS Multistage's "short interest". This figure is 16.3% down from 4,993 last month.
There are a few different ways that this level of interest in shorting NCS Multistage shares can be evaluated.
NCS Multistage's "short interest ratio" (SIR) is the quantity of NCS Multistage shares currently shorted divided by the average quantity of NCS Multistage shares traded daily (recently around 1748.5355648536). NCS Multistage's SIR currently stands at 2.39. In other words for every 100,000 NCS Multistage shares traded daily on the market, roughly 2390 shares are currently held short.
However NCS Multistage's short interest can also be evaluated against the total number of NCS Multistage shares, or, against the total number of tradable NCS Multistage shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NCS Multistage's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NCS Multistage shares in existence, roughly 0 shares are currently held short) or 0.0064% of the tradable shares (for every 100,000 tradable NCS Multistage shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NCS Multistage.
Find out more about how you can short NCS Multistage stock.
We're not expecting NCS Multistage to pay a dividend over the next 12 months.
NCS Multistage's shares were split on a 1:20 basis on 30 November 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NCS Multistage shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NCS Multistage shares which in turn could have impacted NCS Multistage's share price.
Over the last 12 months, NCS Multistage's shares have ranged in value from as little as $11.834 up to $39.195. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NCS Multistage's is 1.8659. This would suggest that NCS Multistage's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NCS Multistage Holdings, Inc. provides engineered products and support services for oil and natural gas well completions and field development strategies in the United States, Canada, and internationally. Its products include casing-installed sliding sleeves, downhole frac isolation assemblies, sand jet perforating products, spotfrac systems, accelus sliding sleeves, airlock casing buoyancy systems, liner hanger systems, and spectrum tracer services. The company also provides advisory services to customers on completion designs and field development strategies. It offers its products and services primarily to exploration and production companies for use in onshore wells through technically-trained direct sales force, and operating partners or sales representatives. The company was formerly known as Pioneer Super Holdings, Inc. and changed its name to NCS Multistage Holdings, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.